BMN: Possible Legislative Changes to Compounding Pharmacies

Articles / Publications
Often times it seems that compounding pharmacies operate in a "gray area" between state legislative oversight and federal legislative oversight. However, due to the attention created by several sterile compounding pharmacies, the federal government is once again proposing ways to regulate the compounding pharmacy industry.
The U.S. Senate recently drafted proposed legislation ("Senate Proposal") targeting compounding pharmacies. The Senate Proposal contains some fundamental changes to compounding pharmacies. For example, the proposed legislation includes compounded drugs within the definition of a "new drug" under the Federal Food, Drug and Cosmetic Act ("FDCA"). This inclusion would create a presumption that compounded drugs have to comply with the burdensome requirements of the FDCA for registration of a new drug and complying with certain manufacturing processes.
To download the full article, click here.

Related Professionals

Burr
Jump to Page
Arrow icon Top

Contact Us

We use cookies to improve your website experience, provide additional security, and remember you when you return to the website. This website does not respond to "Do Not Track" signals. By clicking "Accept," you agree to our use of cookies. To learn more about how we use cookies, please see our Privacy Policy.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.


Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.